

Study Protocol

Estimation of Correlation Between Quetelet's Index and Nottingham Prognostic Index in Patients of Carcinoma Breast: A Study Protocol

ABSTRACT:-

Background – Carcinoma breast is the most prevalent neoplasm in women who have the highest death rate associated with cancer worldwide. In Indian women, breast cancer ranks first followed by cervical cancer with its incidence increasing day by day. Obesity is an important modifiable causative factor of carcinoma breast, associated with a greater chance of contracting breast cancer, as well as with worse prognosis in women of all age groups. It exhibits a state of chronic-inflammation, adipokine-imbalance, insulin-resistance and increased oestrogen-signalling. This pro-tumorigenic environment stimulates development of cancer through abnormal proliferation and survival of breast tissue. Quetelet's Index is most commonly used index to classify obesity, whereas Nottingham Prognostic Index is the most widely used index for longevity assessment and prognosis of breast cancer patients. This study aims to estimate the correlation between Quetelet's index with Nottingham Prognostic Index.

Methods – This prospective observational study will be to be conducted in the Department of Pathology, JNMC, Wardha and AVBRH, Sawangi (Meghe), Wardha in coordination with the Department of General Surgery. Total 35 cases of Carcinoma Breast undergoing Modified Radical Mastectomy will be included in the study. Clinicopathological and anthropometric data of patients will be collected. The Quetelet's Index and the Nottingham Prognostic Index will be determined for each patient and data will be analyzed with appropriate statistical tests to estimate the correlation between them.

Results – Statistically significant correlation is expected between Quetelet's Index and the Nottingham Prognostic Index.

Conclusion - Conclusion will be drawn on positive/negative correlation of Quetelet's Index with different parameters of Nottingham's Prognostic Index.

INTRODUCTION:

Carcinoma breast is the most prevalent neoplasm in women who have the highest death rate associated with cancer worldwide. In Indian women, breast cancer ranks first followed by cervical cancer with its incidence increasing day by day.^[1]

As per WHO, breast carcinoma accounts for 2.09-million cases and 6,27,000-deaths globally which is almost 15% of overall deaths occurring due to carcinomas, among women. According to Globocan-statistics 2018, almost 20.80 lakh women were diagnosed with breast carcinoma and it equated for about 24.2% of overall carcinomas in women, all over the world, making its incidence to about one in every four cancers in women.^[2]




Figure 1: Pie chart showing incidence

In Indian women, breast cancer results in one death every 13 minutes; women in the 30-50 age group are at low risk, while women in the 50-64 age group are at high risk of developing breast carcinoma. Post-cancer survival was estimated to be 60% for Indian women with breast carcinoma, with poor survival rates mostly attributed to late diagnosis.^[3] The various **etiopathological factors** in breast carcinoma include age, genetic-factors, gender, endogenous and exogenous-endocrine factors, child-bearing and fertility, dietary-factors, alcohol, radiation-exposure, benign-duct-diseases, previous history of breast-carcinoma and geographical factors. Heredity plays a major role, responsible for 5-10 percent of cases of breast carcinoma found in first-degree relatives (i.e. mother, daughter, sister or grandma). It is speculated that mutations in either or both of the Breast Cancer gene 1 and Breast Cancer Gene 2 tumor suppressor genes raise the risk of carcinoma breast. Whereas factors such as breastfeeding, first pregnancy < 25 years of age, multiple pregnancy < 25 years of age, daily exercise and Asian descent are thought to decrease the risk of carcinoma breast.^[3]

Obesity is an important modifiable causative factor of carcinoma breast, associated with a greater chance of contracting breast cancer, as well as with worse prognosis in women of all age groups. It exhibits a state of chronic-inflammation, adipokine-imbalance, insulin-resistance and increased oestrogen-signalling. This pro-tumorigenic environment stimulates development of cancer through abnormal proliferation and survival of breast tissue. It is suspected that it raises the proinflammatory cytokines; both local and circulating, promotes tumour vascularization and also activates the most malignant stem cells, which causes increased tumour cell formation, invasion and metastasis.^[4] In addition to this, it also accounts for increased risk of complications associated with all of the treatment modalities (surgery, chemotherapy, radiation) in carcinoma-breast.

Body mass index (Quetelet's Index) is a simple and the most commonly used index used to classify obesity, as it is the same for both genders and for any age of adults. It is defined as the weight ratio of an individual in kgs to square of height in meters. (kg/m^2). It can be measured by using the **formula** $\text{Quetelet's Index} = \text{Weight}(\text{kg}) / [\text{Height}(\text{m})]^2$. Studies suggest that women with higher Quetelet's Index may be associated with higher grade, increased aggressiveness of tumour, an increased risk of recurrence and mortality and those with lower BMI are relatively at a lower-risk of developing breast carcinoma and may be related with a lower grade of tumour in patients having carcinoma breast.^[1] A few

studies suggest that increased tumour proliferation is the trajectory which explains the cause of the worse outcome of carcinoma breast among obese ladies.^[5]

To estimate survival and the risk of recurrence in breast carcinoma cases, a variety of prognostic factors have been identified. Nevertheless, it cannot be speculated which aspect predominates above the others in breast cancer prognosis.^[3] Therefore there has been an attempt to amalgamate each of these variables into some important indexes and grading systems.

The Nottingham Prognostic Index is the most widely used index for longevity assessment and prognosis of breast cancer patients, taking into account the following three variables –

- Size of the tumour
- Status of lymph node
- Modified Bloom Richardson's grading of the tumour.^[6]

In numerous studies, it has helped to discern patients on the basis of aggressiveness of the tumour and has become an important prognostic aid in determining outcome of patients with breast-carcinoma. The present study is designed with an aim to establish a correlation between Quetelet's index and Nottingham Prognostic Index for determining the effect of obesity on aggressiveness of the tumour, predicting the survival of patients with breast-carcinoma.

RATIONALE:

Carcinoma Breast is one of the most prevalent causes of death worldwide, with a growing prevalence every day. Obesity is a growing plight all over the world that plays a key part in the growth and propagation of the tumor. It's a modifiable risk factor. Behavioural changes (dietary and exercise) may also lead to changes in tumorigenesis, insulin-sensitivity, circulating oestrogen and oxidative stress in response to weight loss. Obesity-reduction techniques can prove to be cost-effective strategies for reducing the risk and improving outcomes in the patients with Carcinoma Breast. The Quetelet's index, which is the most widely used measure of obesity, has to be compared with the Nottingham Prognostic Index (NPI) to assess patients' outcomes; thereby being an adjunct to breast carcinoma prognosis.

RESEARCH GAP:

The present study aims to close the gap of understanding between correlation of Quetelet's Index which is a direct measure of obesity, with Nottingham's Prognostic Index in Carcinoma Breast. It will enable to breach the gap of understanding the relationship between obesity and the tumour size, histological grade and the lymph node metastasis in Carcinoma Breast. It will help to create a frame for early, cost-effective strategies for reducing breast-cancer risk and improving breast-cancer outcome.

RESEARCH QUESTION:

With understanding the effect of obesity on aggressiveness and proliferation of tumour cells in Carcinoma Breast, the following research question is framed –

'Does Quetelet's Index have a significant association with the size of the tumour, histological-grade and lymph node metastasis i.e. Nottingham's Prognostic Index in Carcinoma Breast.'

METHODOLOGY:

STUDY DESIGN – Observational, analytical, cross-sectional and prospective.

PLACE OF STUDY – Department of Pathology, JNMC, Sawangi (Meghe), Wardha, Maharashtra.

DURATION – 2020 to 2022 (2 years)

METHODS –

- An Institutional Ethics Committee Clearance will be obtained before the start of the study.
- Prior written consent will be received from all patients involved in the study.
- Medical records will be taken and an adequate physical examination will be carried out in all patients.
- The anthropometric data like history of built and size of their body, along with their adult weight as well as height 1 year before diagnosis, highest average weight and weight at eighteen years of age will be obtained from the respondents.
- Weight (in kgs.) and height (in meters) will be measured and Quetelet's Index will be calculated for each case.
- In addition to BMI, we will measure patients' waist and hip circumference as anthropometric indicators of obesity in relation to the likelihood of breast cancer.
- Modified Radical Mastectomy specimens of cases confirmed as Carcinoma Breast will be obtained in 10% of Formalin and the resected specimens shall be kept in 10% of formalin for 12-24 hours for fixation.
- Dissection of the received specimens and appropriate sections from the margins, tumour mass and axillary lymph nodes will be done.
- Specimens will be subjected to routine tissue processing after which routine Haematoxylin and Eosin staining will be carried out.
- The histological grade of the tumour will be determined by the Nottingham modification of Bloom-Richardson Grading System.
- Grade of the tumour will be taken as Grade I equal to one, Grade II equal to two and Grade III equal to three.
- The Nottingham Prognostic Index of each case will be calculated by evaluating the size of the tumour, status of the lymph nodes and histological grade.
Formula used will be: $NPI = [0.2 \times \text{lesion's size (in centimetres)}] + \text{status of the lymph nodes} + \text{tumour's grade}$.
- Where, 0 nodes = 1; 1-3 nodes = 2; >3 nodes = 3 and grade will be calculated as Grade I equal to one, Grade II equal to two and Grade III equal to three.
- After which, correlation of Body Mass Index of each case with its Nottingham's Prognostic Index will be done.

SAMPLE SIZE – 35 patients

The sample size was calculated by using Krejcie and Morgan formula with desired error of margin:

$$n = \frac{(Z \alpha/2)^2 \times p \times (1-p)}{d^2}$$

where,

$Z\alpha/2$ is the level of significance at 5% i.e. 95 % confidence interval = 1.96

p = Prevalence of breast carcinoma = 0.33% = 0.033^[2]

d = Desired error of margin = 6% = 0.06

$$n = \text{Sample size} = \frac{(1.96)^2 \times 0.033 \times (1 - 0.033)}{(0.06)^2} = 34.05$$

n = 35 (35 patients will be needed in the study).

Inclusion Criteria:

1. All cases diagnosed as Carcinoma Breast on histopathology.
2. All cases in which Modified Radical Mastectomy has been done.
3. All female patients presenting with Carcinoma Breast.
4. Primary cases of Carcinoma Breast without any history of previous treatment.
5. All cases of Carcinoma Breast having complete height and weight data.

Exclusion Criteria:

1. All cases other than carcinoma breast and cases with metastatic deposits.
2. All cases where only trucut biopsy, wedge biopsy or lobectomy has been done.
3. All cases of myoepithelial lesions, mesenchymal and fibroepithelial tumours, tumours involving nipple, metastatic tumours and adenomas.
4. All male patients presenting with Carcinoma Breast.
5. Cases with a history of neoadjuvant therapy.
6. All cases of Carcinoma Breast having incomplete height and weight data.

Statistical Analysis

Statistical research will be carried out using the 'Chi Square Test' where statistical significance will be assumed to imply a value of P less than 0.05.

PRELIMINARY DATA RECORDING –

- i. Name:
- ii. Age/Sex:
- iii. Registration Number:
- iv. Nature of the Specimen:
- v. Local examination of breast:
- vi. Comorbidities:
- vii. Diagnosis on Histopathological Examination:
- viii. Height(cm.):

- ix. Weight(kgs.):
- x. Waist circumference:

EXPECTED RESULTS:

The study will be conducted for a period of 2 years and all the observations will be depicted in a well-tabulated master chart.

DISCUSSION:

Breast carcinoma is a heterogeneous disorder that differs by genetic subtype, clinicopathological manifestations, prognosis and care. The features of the tumor and its response to various management plans vary depending on the level and grade of the tumor as well as the expression of the different receptors. Tumors are histologically categorized by their receptor positivity, namely estrogen, progesterone and human epidermal growth factor receptor-2 (ER, PR and HER2). A variety of causes have been found to affect an individual's risk of contracting carcinoma breast and on their overall prognosis.^[7]

Obesity, that is Body Mass Index more than 30 kg/m² is a significant risk factor that leads to a higher chance of contracting breast cancer. It has also been found to be correlated with a larger size of the tumor, relatively high proliferative index as well as histological score, according to some research.^[1]

A short review for the present work is entitled below, citing the studies from different centres establishing the correlation of Quetelet's Index with different parameters of Nottingham's Prognostic Index.

Janet R. Daling et al., conducted a study entitled "Relation of Body Mass Index with Tumour Markers and Survival among Young Women with Invasive-Ductal Breast-Carcinoma", which was population-based follow-up study of 1177 women under the age of 45 who were diagnosed with breast carcinoma (Invasive ductal type) from 1983 to 1992. The study found that women in the maximum BMI range diagnosed with breast carcinoma at a young age had a poor survival rate and were associated with higher mortality rate. The tumours of overweight cases were considerably larger and associated with markers of elevated proliferative potential of the cells than those of smaller women.^[8]

Nehad M. Ayoub et al, published an article titled "Impact of Obesity on Clinicopathological Characteristics and Prognosis of disease in Pre-and Postmenopausal Breast Cancer Patients: A Retrospective Institutional Study" in which they reviewed the medical records and the electronic database of 348 patients who were diagnosed as breast carcinoma cases histologically, over a period of eleven years from 2004 to 2014. The result of the study found that obesity in contrast to non obese patients at diagnosis was correlated with advanced stage and classification of breast carcinoma as well as poor prognostic characteristics at cancer presentation.^[9]

Blair, Cindy K., et al., published an article titled "Obesity and survival among group of breast cancer patients is partially mediated by characteristics of the tumour" in which the role of obesity on survival was determined among 859 cases with incidence of carcinoma breast and 697 deaths from breast-cancer over a period of six years, from 1997 and 2009. The conclusion of study showed that obese and overweight cases had respectively, 1.7- and 1.8-times rise in the risk of stage third and fourth cancer and tumours of grade 3/4.^[10]

Comment [WS1]: Is the date (1997 to 2009) only 6 years correct?

Wang, Junyi, et al. published an article titled “Body Mass Index Increases the Lymph-Node Metastasis Risk of Carcinoma Breast” in which they total 20 studies with 52,904 cases until November 2019 were encompassed. A 2 stage random impact meta-analysis was conducted to check the relationship between Quetelet’s Index and risk of metastasis of the lymph node. Their studies concluded that BMI greatly raises the risk of lymph node metastases in Carcinoma Breast.^[11]

Keskin O et al. conducted a retrospective cohort study entitled "Impact of lymph node obesity in operable breast cancer patients," involving 1,295 patients with axillary dissection and review of the association between Quetelet’s Index and patient and tumour characteristics, in particular status of the lymph nodes. The study concluded that the number of the dissection of lymph nodes was significantly higher in obese patients, but there was no connection between the proportion of lymph nodes which were positive for infiltration by malignant cells and BMI.^[12]

A number of related studies were reported ^[13-15]. Goyal et. al. reported on Utility of micro vessel density and it’s correlation with Nottingham prognostic index in carcinoma breast^[16]. Few of the studies on different diagnostic approaches and related aspects of carcinoma breast were reviewed ^[17-21]. Wagh et. al. reported a study on relationship between hypothyroidism and body mass index in women ^[22-28].

REFERENCES

1. GOVIND BABU, K., ANAND, A., LOKANATHA, D. and KOPPAKA, D., 2018. Correlation of BMI with breast cancer subtype and tumour size. *Ecancermedicalscience*, 12.
2. GLOBOCAN PROJECT 2018: Statistic of Breast cancer in India: Global comparison
3. Abdulkareem IH. Aetio-pathogenesis of breast cancer. *Niger Med J*. 2013 Nov;54(6):371–5.
4. Picon-Ruiz, Manuel, et al. “Obesity and Adverse Breast Cancer Risk and Outcome: Mechanistic Insights and Strategies for Intervention.” *CA: A Cancer Journal for Clinicians*, vol. 67, no. 5, Sept. 2017, pp. 378–97.
5. Kamineni, Aruna, et al. “Body Mass Index, Tumor Characteristics, and Prognosis Following Diagnosis of Early-Stage Breast Cancer in a Mammographically Screened Population.” *Cancer Causes & Control*, vol. 24, no. 2, Feb. 2013, pp. 305–12.
6. Nalwoga, Hawa. “A study with focus on molecular phenotypes, angiogenesis and stem cells in an African population.” The Gade Institute, Section for Pathology University of Bergen NORWAY, 2010
7. Gershuni VM, Ahima RS, Tchou J. Obesity and Breast Cancer: A Complex Relationship. *CurrSurg Rep*. 2016 Apr;4.
8. R. Daling, J., E. Malone, K., R. Doody, D. and G. Johnson, L., 2020. Relation of Body Mass Index to Tumor Markers and Survival among Young Women with Invasive Ductal Breast Carcinoma. *CANCER*, 92, pp.720-29.
9. Ayoub, Nehad M., et al. “Impact of Obesity on Clinicopathologic Characteristics and Disease Prognosis in Pre- and Postmenopausal Breast Cancer Patients: A Retrospective Institutional Study.” *Journal of Obesity*, vol. 2019, Mar. 2019, pp. 1–11.
10. Blair, Cindy K., et al. “Obesity and Survival among a Cohort of Breast Cancer Patients Is Partially Mediated by Tumor Characteristics.” *Npj Breast Cancer*, vol. 5, no. 1, Dec. 2019, p. 33.

11. Wang, Junyi, et al. "Body Mass Index Increases the Lymph Node Metastasis Risk of Breast Cancer: A Dose-Response Meta-Analysis with 52904 Subjects from 20 Cohort Studies." *BMC Cancer*, vol. 20, no. 1, Dec. 2020, p. 601.
12. Keskin O, Aksoy S, Babacan T, Sarici F, Kertmen N, Solak M, Turkoz FP, Arik Z, Esin E, Petekkaya I, Altundag K. Impact of the obesity on lymph node status in operable breast cancer patients. *J BUON*. 2013 Oct-Dec;18(4):824-30. PMID: 24344004.
13. Jain, A., A. Bhake, S. Vagha, and R. Narkhede. "Correlation of Carcinoma Antigen (Ca 15-3) Serum Assay with Clinicopathological Parameters in Women with Invasive Ductal Carcinoma." *International Journal of Pharmaceutical Research* 11, no. 1 (2019): 1193–97. <https://doi.org/10.31838/ijpr/2019.11.01.211>.
14. Jaiswal, N., J. Makrande, A. Bhake, and A.V. Bapat. "Ema, Vimentin, Desmin, Calretinin, e-Cadherin on Cell Block to Differentiate Adenocarcinoma Cells from Benign Reactive Mesothelial Cells." *International Journal of Pharmaceutical Research* 11, no. 2 (2019): 1860–64. <https://doi.org/10.31838/ijpr/2019.11.02.213>.
15. Mishra, P., S. Vagha, S. Shukla, and S.S. Chaudhari. "Correlation of Cytokeratin Expression with Bloom Richardson Grading of Carcinoma Breast in Rural Setup." *International Journal of Pharmaceutical Research* 11, no. 2 (2019): 1844–48. <https://doi.org/10.31838/ijpr/2019.11.02.209>.
16. Goyal A. , Shukla S., Vagha S. , Acharya S., Jagtap M., and Kumbhare J. "Utility of Microvessel Density and It's Correlation with Nottingham Prognostic Index in Carcinoma Breast." *International Journal of Pharmaceutical Research* 11, no. 4 (2019): 2013–17. <https://doi.org/10.31838/ijpr/2019.11.04.502>.
17. Wankhade, R., V. Gupta, and A. Belsare. "Role of Ki 67 in Pathological Prognostic Staging of Breast Cancer." *International Journal of Pharmaceutical Research* 11, no. 3 (2019): 1469–73. <https://doi.org/10.31838/ijpr/2019.11.03.164>.
18. Domkunti, R., Y.R. Lamture, A. Rinait, and D. Gode. "Breast Carcinoma in Axillary Tail of Spence: A Rare Case Report." *International Journal of Current Research and Review* 12, no. 14 Special Issue (2020): 92–95. <https://doi.org/10.31782/IJCRR.2020.9295>.
19. Hemant, L.H., H. Keshao, V. Sunita, and C.S. Gode. "Correlation of Total Serum LDH Levels with Differentiation of Breast Carcinoma." *International Journal of Pharmaceutical Research* 11, no. 1 (2019): 1211–15. <https://doi.org/10.31838/ijpr/2019.11.01.214>.
20. Kishor, T.A., H.K. Madhavrao, V. Sunit, and P. Palsodkar. "Study of Androgen Receptor as a Quadruple Marker in Breast Carcinoma." *International Journal of Pharmaceutical Research* 11, no. 1 (2019): 1173–78. <https://doi.org/10.31838/ijpr/2019.11.01.208>.
21. Kumar, S., L. Jena, M. Sahoo, K. Mohod, S. Daf, and A.K. Varma. "Effect of Single Amino Acid Mutations on C-Terminal Domain of Breast Cancer Susceptible Protein 1." *International Journal of Bioinformatics Research and Applications* 15, no. 4 (2019): 305–23. <https://doi.org/10.1504/IJBRA.2019.103783>.
22. Wagh, S.P., S.P. Bhagat, N. Bankar, and K. Jain. "Relationship between Hypothyroidism and Body Mass Index in Women: A Cross-Sectional Study." *International Journal of Current Research and Review* 12, no. 12 (2020): 48–51. <https://doi.org/10.31782/IJCRR.2020.12129>.
23. Nagrale AV, Glynn P, Joshi A, Ramteke G. The efficacy of an integrated neuromuscular inhibition technique on upper trapezius trigger points in subjects with non-specific neck pain: a randomized controlled trial. *Journal of Manual & Manipulative Therapy*. 2010 Mar 1;18(1):37-43.

24. Bourne R, Steinmetz JD, Flaxman S, Briant PS, Taylor HR, Resnikoff S, Casson RJ, Abdoli A, Abu-Gharbieh E, Afshin A, Ahmadieh H. Trends in prevalence of blindness and distance and near vision impairment over 30 years: an analysis for the Global Burden of Disease Study. *The Lancet Global Health*. 2021 Feb 1;9(2):e130-43.
25. Agrawal A, Cincu R, Goel A. Current concepts and controversies in the management of non-functioning giant pituitary macroadenomas. *Clinical neurology and neurosurgery*. 2007 Oct 1;109(8):645-50.
26. Franklin RC, Peden AE, Hamilton EB, Bisignano C, Castle CD, Dingels ZV, Hay SI, Liu Z, Mokdad AH, Roberts NL, Sylte DO. The burden of unintentional drowning: global, regional and national estimates of mortality from the Global Burden of Disease 2017 Study. *Injury prevention*. 2020 Oct 1;26(Suppl 1):i83-95.
27. Chole RH, Gondivkar SM, Gadbail AR, Balsaraf S, Chaudhary S, Dhore SV, Ghonmode S, Balwani S, Mankar M, Tiwari M, Parikh RV. Review of drug treatment of oral submucous fibrosis. *Oral oncology*. 2012 May 1;48(5):393-8.
28. Korde SD, Basak A, Chaudhary M, Goyal M, Vagga A. Enhanced nitrosative and oxidative stress with decreased total antioxidant capacity in patients with oral precancer and oral squamous cell carcinoma. *Oncology*. 2011;80(5-6):382-9.

UNDER PEER REVIEW